Daily Cardiology Research Analysis
Analyzed 63 papers and selected 3 impactful papers.
Summary
Analyzed 63 papers and selected 3 impactful articles.
Selected Articles
1. Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR): a randomised controlled trial.
In 2,476 women with suspected ANOCA/INOCA, intensive medical therapy (high-intensity statin, ACEi/ARB, aspirin) did not reduce major adverse cardiovascular events over 2.5 years compared with usual care. Events were dominated by angina hospitalizations, underscoring high symptom burden despite well-controlled baseline risk factors.
Impact: This is a large randomized, blinded-outcome trial in a high-need population, delivering a practice-informing negative result that challenges empiric blanket use of intensive medical therapy in women with ANOCA/INOCA.
Clinical Implications: Routine intensification of statin/ACEi/ARB plus aspirin may not reduce hard events in women with suspected ANOCA/INOCA; management should prioritize symptom-directed strategies and endotype-guided care while awaiting adequately powered, mechanism-based trials.
Key Findings
- Primary MACE showed no reduction with intensive medical therapy vs usual care (HR 1.13, 95% CI 0.94–1.37; p=0.20) over 2.5 years.
- Angina hospitalizations were the dominant contributor to events, indicating high symptom burden.
- Baseline medical therapy use was high, limiting treatment contrast; sensitivity analysis suggested potential contamination effects.
Methodological Strengths
- Randomized, multicenter design with blinded outcome adjudication
- Pre-specified endpoints and large sample size across 71 sites
Limitations
- Lower-than-planned recruitment reduced statistical power
- High baseline use of statins and ACEi/ARB limited treatment contrast and potential effect size
Future Directions: Mechanism-targeted, adequately powered trials stratified by endotypes (microvascular dysfunction, vasospasm) and symptom-directed pathways; pragmatic strategies to reduce angina hospitalizations and improve quality of life.
IMPORTANCE: Women with angina due to suspected ischaemia referred for coronary angiography often have no obstructive coronary artery disease (ANOCA/INOCA). OBJECTIVE: To determine if intensive medical treatment (IMT) reduces major ischaemic events (major adverse cardiovascular event, MACE) among women with suspected ANOCA/INOCA. DESIGN: Randomised, prospective, blinded-outcomes evaluation. SETTING: 71 sites in the USA. PARTICIPANTS: 2476 women with suspected ANOCA/INOCA. INTERVENTIONS: IMT-high intensity statin, ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) and aspirin versus usual care (UC). MAIN OUTCOMES AND MEASURES: Primary: all cause death, myocardial infarction, stroke/transient ischaemic attack, hospitalisation for angina or heart failure (MACE). Secondary: components of the primary, quality of life and win ratio. RESULTS: Recruitment was lower than planned (n=2476), yielding an aged population (mean, 64 years) with well-controlled blood pressure and low-density lipoprotein cholesterol at baseline, and relatively high rates of statin and ACEI/ARB use. At 2.5 years, 421 events occurred (221 in IMT, 200 in UC) with no difference in the primary outcome (HR=1.13 (95% CI 0.94 to 1.37) for IMT vs UC, p=0.20) or secondary outcomes. Hospitalisations for angina were the dominant contributor to MACE. Sensitivity analysis of contamination provided an estimated HR for IMT versus UC of 0.74 95% CI (0.352 to 1.558), p=0.43. CONCLUSIONS AND RELEVANCE: Among women with suspected ANOCA/INOCA, outcomes were dominated by chest pain and IMT did not improve outcomes, although limited power precludes concluding that it may not be helpful. The findings support the need for more investigation in this population with high burden of angina hospitalisation, health resource consumption and poor quality of life. TRIAL REGISTRATION NUMBER: NCT03417388.
2. Fibroelastic remodeling of the endocardium on the right side of the heart: Endothelial-to-mesenchymal transition in pulmonary atresia with intact ventricular septum.
Human surgical tissue and flow-mimetic experiments demonstrate that pathological flow triggers endothelial-to-mesenchymal transition of endocardial endothelial cells, driving subendocardial fibroelastic remodeling and right ventricular diastolic dysfunction in PA/cPS-IVS. These data nominate fibrogenic/EndMT pathways as therapeutic targets.
Impact: This mechanistic study extends EndMT-driven fibroelastic remodeling from left-sided disease to right-sided congenital lesions, providing a unifying flow-based pathophysiology and actionable targets.
Clinical Implications: Although preclinical, the findings support exploring anti-fibrogenic and anti-EndMT strategies to preserve RV compliance in PA/cPS-IVS and inform timing and goals of surgical interventions.
Key Findings
- All 13 patients exhibited flow disturbances across pulmonary and/or tricuspid valves.
- Resected right ventricular subendocardium showed active fibroelastic remodeling infiltrating the myocardium with elevated filling pressures indicating diastolic dysfunction.
- Pathological flow exposure induced EndMT in isolated endocardial endothelial cells, recapitulating human disease mechanisms.
Methodological Strengths
- Integration of human surgical tissue analysis with in vitro flow-mimetic EndMT modeling
- Multimodal assessment (histology, immunohistochemistry, flow cytometry) strengthening mechanistic inference
Limitations
- Small single-center cohort (n=13) limits generalizability
- No interventional testing of anti-EndMT/fibrogenic pathway inhibition and no longitudinal outcomes
Future Directions: In vivo validation and therapeutic modulation of EndMT/fibrogenic signaling; development of flow-based biomarkers and imaging for risk stratification and treatment monitoring.
OBJECTIVES: Patients with pulmonary atresia/critical pulmonary stenosis with intact ventricular septum (PA/cPS-IVS) show fibrous subendocardial tissue of unclear origin accompanied by right ventricular (RV) hypoplasia. While in hypoplastic left heart syndrome it is known that flow-induced endothelial-to-mesenchymal transition (EndMT) of endocardial endothelial cells (EECs) is the source of this fibrous tissue, it remains unclear whether similar mechanisms exist in PA/cPS-IVS. METHODS: We analyzed 13 PA/cPS-IVS patients who underwent staged ventricular rehabilitation surgery aimed at preserving RV function between March 2021 and July 2025 at Boston Children's Hospital. Resected tissue was examined for the degree of fibrosis and elastin, and the presence of active EndMT by histology, immunohistochemistry, and flow cytometry. To mimic human disease conditions, isolated EECs were exposed to pathological flow and compared with physiological flow conditions. RESULTS: Flow disturbances across the pulmonary and/or tricuspid valves were present in all patients. Resected RV tissue revealed an active subendocardial fibroelastic remodeling process, infiltrating into the underlying myocardium. Patients showed RV diastolic dysfunction, as evidenced by elevated filling pressures, suggesting a pathophysiological role of fibroelastic remodeling of the endocardium. Mimicking the human disease, exposure of isolated EECs to pathological flow conditions induced loss of endothelial characteristics and transition toward a mesenchymal phenotype through EndMT. CONCLUSIONS: In PA/cPS-IVS patients, restrictive RV physiology and diastolic dysfunction are likely driven by infiltrative fibroelastic remodeling caused by localized fibrogenic activation of EECs through EndMT in response to flow disturbances from valvular defects. Fibrogenic pathway activation may represent a promising therapeutic target in PA/cPS-IVS.
3. Intra-aortic balloon support for myocardial infarction with cardiogenic shock: insights from the Swedish Coronary Angiography and Angioplasty Registry.
In 2,991 MI-related cardiogenic shock patients from a national registry, IABP was not associated with lower 30-day or 1-year mortality using instrumental variable analysis but was linked to a 26% absolute increase in in-hospital complications. Findings reinforce guideline recommendations against routine IABP use.
Impact: High-quality real-world evidence with causal inference methods confirms lack of survival benefit and highlights harm signals, directly informing acute shock management.
Clinical Implications: Avoid routine IABP in MI-related shock; prioritize alternative strategies and enroll patients in trials evaluating contemporary MCS and shock protocols while weighing complication risk.
Key Findings
- No mortality reduction at 30 days (risk reduction −1.1%, 95% CI −15.7 to 13.5; P=0.881) or 1 year (−0.8%, 95% CI −23.2 to 0.06; P=0.258) with IABP.
- IABP associated with a 26.1% increase in in-hospital complications (95% CI 15.2–36.8; P<0.001).
- Overall mortality remained high (30-day 52%; 1-year 63.2%) in MI-related cardiogenic shock.
Methodological Strengths
- Nationwide prospective registry across 31 centers with large sample size
- Instrumental variable analysis using hospital treatment preference to mitigate confounding by indication
Limitations
- Observational design with potential residual confounding despite instrumental variable approach
- Limited granularity on concurrent shock therapies and timing of IABP initiation
Future Directions: Randomized and adaptive trials of contemporary mechanical circulatory support and shock protocols; risk-benefit stratification tools incorporating complication risks.
BACKGROUND: Cardiogenic shock remains the leading cause of in-hospital death in patients with acute myocardial infarction (MI). The intra-aortic balloon pump (IABP), once widely used, was downgraded in European guidelines after a major randomized trial showed no mortality benefit. This prospective observational study evaluated the impact of IABP on 30-day mortality and in-hospital complications in real-world patients with MI complicated by cardiogenic shock. METHODS: Data were obtained from the Swedish Coronary Angiography and Angioplasty Registry, including all percutaneous coronary intervention procedures performed across 31 hospitals in Sweden between 2005 and 2018. A total of 2991 patients with cardiogenic shock were included, of whom 737 (25%) received IABP. To account for baseline differences, instrumental variable analysis was applied using hospital treatment preference as the instrument. RESULTS: At 30 days, 52% of patients had died, and by 1 year, mortality reached 63.2%. In-hospital complications occurred in 13.4% of patients. IABP treatment was not associated with reduced mortality at 30 days [risk reduction: -1.1%, 95% confidence interval (CI): -15.7 to 13.5; P = 0.881] or at 1 year (risk reduction: -0.8%, 95% CI: -23.2 to 0.06; P = 0.258). However, IABP use was associated with a significantly higher risk of in-hospital complications (increase of 26.1%, 95% CI: 15.2-36.8; P < 0.001). CONCLUSION: IABP did not improve short- or long-term survival in patients with MI-related cardiogenic shock but was linked to increased complications, supporting current guideline recommendations against its routine use.